NDABUCCALGUM, CHEWINGPriority Review
Approved
Jan 1984
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Data completeness
3/8 — Basic
Priority Review
NICORETTE (MINT) (nicotine polacrilex) by GSK. Approved for nicotine dependence, cigarette smoking behavior. First approved in 1984.
Drug data last refreshed 19h ago
Mechanism of Action
Pharmacologic Class:
Cholinergic Nicotinic Agonist
Indications (2)
Worked on NICORETTE (MINT) at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.